Frontiers in Oncology · 2012 · 33 citations · 89 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyRadiation ProtectionRadiobiologyBiological Effects Of RadiationPatient Radiation ProtectionRadiation HealthRadiation SensitivityRadiation TherapyRadiation ToxicityFractionated TreatmentHybrid MoleculesNormal Tissue RadiosensitivityRadiation DamageRadiation-induced Hematopoietic InjuryRadioprotection MechanismsRadioprotective EffectsRadioprotective Mechanisms
Mitochondrial targeted radiation damage protectors (delivered prior to irradiation) and mitigators (delivered after irradiation, but before the appearance of symptoms associated with radiation syndrome) have been a recent focus in drug discovery for (1) normal tissue radiation protection during fractionated radiotherapy, and (2) radiation terrorism counter measures. Several categories of such molecules have been discovered: nitroxide-linked hybrid molecules, including GS-nitroxide, GS-nitric oxide synthase inhibitors, p53/mdm2/mdm4 inhibitors, and pharmaceutical agents including inhibitors of the phosphoinositide-3-kinase pathway and the anti-seizure medicine, carbamazepine. Evaluation of potential new radiation dose modifying molecules to protect normal tissue includes: clonogenic radiation survival curves, assays for apoptosis and DNA repair, and irradiation-induced depletion of antioxidant stores. Studies of organ specific radioprotection and in total body irradiation-induced hematopoietic syndrome in the mouse model for protection/mitigation facilitate rational means by which to move candidate small molecule drugs along the drug discovery pipeline into clinical development.
89
Radiobiology for the Radiologist.
Annals of Internal Medicine · 1974 · 3.5K citations
Radiobiology for the Radiologist
R. J. M. Fry, Eric J. Hall · Radiation Research · 1995 · 1.3K citations